Search
Close this search box.
NYSE American: IGC

Investor
Relations

Inspire. Grow. Care.

Explore our Deck

Find the company overview and discover with us exciting scientific developments and business opportunities.

Read More

Latest News

IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a “Buy” Recommendation and $3.50 Price Target

July 18, 2024

Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile

July 9, 2024

IGC Pharma’s TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer’s Disease

June 25, 2024

IGC Reports Financial Results for Fiscal Year Ended March 31, 2024

June 24, 2024
View All

SEC Filings

IGC Pharma DEF 14A 07-05-24 AS FILED

July 12, 2024

IGC FYE2024 Annual Meeting PROXY CARD

July 9, 2024

Annual Shareholder Letter July 2024

July 9, 2024

IGC Pharma DEFA 14A 07-09-24

July 9, 2024
View All

From the CEO's desk:
Vertical integration

Periodic updates and perspectives on various aspects of our business.

Read More

Our Research

IGC-AD1

Is designed to target neuroinflammation, potentially stabilize CB1r function and address neurotransmitter imbalances, all hallmarks associated with agitation in Alzheimer Dementia
Learn more

TGR-63

A small molecule designed to break down plaque formation in the brain, exhibiting outstanding biocompatibility, the ability to breach the blood–brain barrier, and pre-clinical behavioral efficacy.
Learn more

A.I.

To mine the depths of decades-worth of Alzheimer’s research, bringing to light novel insights and pioneering advanced treatments faster than ever for a healthier elderliness.
Learn more

Science

IGC Pharma is actively building a portfolio of both plant-derived and manufactured molecules that can address multiple areas of unmet medical needs.
Patents
Pipeline

Locations

Our company has operations in different countries
manufacturing vertical and R&D capabilities.

No thanks.

NOTICE OF IGC PHARMA INC. 2024 ANNUAL MEETING OF SHAREHOLDERS

  • Friday August 23, 2024, Time 11:00 a.m. Eastern Time
  • 10224 Falls Road, Potomac, Maryland

 

Purpose
1. To elect Mr. Richard Prins and Mr. Terry Lierman to the Company’s board of directors to serve as Class B directors until the 2027 Annual Meeting of Stockholders.

2. To ratify the appointment of Manohar Chowdhry & Associates, as the Company’s independent registered public accounting firm for the 2025 fiscal year.

3. To approve the grant of 5,000,000 shares of common stock, governed by the Company’s 2018 Omnibus Incentive Plan, to be granted from time to time to the Company’s current and new employees, advisors, directors, and consultants by the board of directors, pursuant to certain metrics including performance, vesting, and incentive as set by the board of directors and or the CEO.

4. To act upon such other matters as may properly come before the Annual Meeting, including any proposal to adjourn or postpone the Annual Meeting.

Record Date

The directors have fixed the close of business on June 28, 2024, as the record date for determining shareholders entitled to notice of and to vote at the meeting.

By Order of the Board of Directors of IGC Pharma Inc.